Nuciferine

Catalog No.S3821 Batch:S382103

Technical Data

Formula

C₁₉H₂₁NO₂

Molecular Weight

295.38

CAS No.

475-83-2

Solubility (25°C)*

In vitro

DMSO

7 mg/mL (23.69 mM)

Water

Insoluble

Ethanol

Insoluble

In vivo (Add solvents to the product individually and in order)

Clear solution	5% DMSO 1 95% Corn oil	0.35mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 7 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O	0.35mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 7 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	Nuciferine (Sanjoinine E, (-)-Nuciferine, VLT 049) is a major active aporphine alkaloid from the leaves of N. nucifera Gaertn and possesses anti-hyperlipidemia, anti-hypotensive, anti-arrhythmic, and insulin secretagogue activities. Nuciferine is an antagonist at 5-HT2A (IC50=478 nM), 5-HT2C (IC50=131 nM), and 5-HT2B (IC50=1 μM), an inverse agonist at 5-HT7 (IC50=150 nM), a partial agonist at D2 (EC50=64 nM), D5 (EC50=2.6 μM) and 5-HT6 (EC50=700 nM), an agonist at 5-HT1A (EC50=3.2 μM) and D4 (EC50=2 μM) receptor.
In vitro	Nuciferine inhibits the growth of MDA-MB-231 and MCF-7 human breast cancer cells by inducing apoptosis and inhibiting proliferation via cell cycle arrest. Nuciferine inhibits the receptor activator of nuclear factor kappa-B ligand- (RANKL-) induced osteoclast differentiation in mouse bone marrow macrophage cells and mature osteoclast-mediated bone resorption. It reduces the viability of SY5Y human neuroblastoma cells and CT26 murine colon cancer cells, inhibits nicotine-induced non-small-cell lung cancer progression^[1].
In vivo	Nuciferine is found to decrease serum urate levels and improve kidney function, as well as inhibit system and renal interleukin-1β (IL-1β) secretion in potassium oxonate-induced hyperuricemic mice. Furthermore, nuciferine reverses expression alteration of renal urate transporter 1 (URAT1), glucose transporter 9 (GLUT9), ATP-binding cassette, subfamily G, membrane 2 (ABCG2), organic anion transporter 1 (OAT1), organic cation transporter 1 (OCT1), and organic cation/carnitine transporters 1/2 (OCTN1/2) in hyperuricemic mice. It also suppresses renal activation of TLR4/MyD88/NF-κB signaling and NOD-like receptor family, NLRP3 inflammasome to reduce serum and renal IL-1β levels in hyperuricemic mice with renal inflammation reduction^[2].

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines MDA-MB-231 or MCF-7 cells Concentrations 0, 20, 40, 60 μM Incubation Time 24 hours Method MDA-MB-231 or MCF-7 cells (5 × 10³ cells/well) are cultured in serum-free media with the various concentrations of liensinine or nuciferine in the absence or presence of zVAD-fmk (10 μM) for 24 h. Bone marrow macrophages (5 × 10⁴ cells/well) are cultured in serum-free medium with liensinine or nuciferine at the indicated concentrations for 5 days. Cell viability is measured with an MTT assay.
Animal Study:^{^[2]}	Animal Models Male Kun-Ming strain of mice Dosages 10, 20 and 40 mg/kg Administration by oral gavage

Cell Assay:^{^[1]}

Cell lines
MDA-MB-231 or MCF-7 cells
Concentrations
0, 20, 40, 60 μM
Incubation Time
24 hours
Method
MDA-MB-231 or MCF-7 cells (5 × 10³ cells/well) are cultured in serum-free media with the various concentrations of liensinine or nuciferine in the absence or presence of zVAD-fmk (10 μM) for 24 h. Bone marrow macrophages (5 × 10⁴ cells/well) are cultured in serum-free medium with liensinine or nuciferine at the indicated concentrations for 5 days. Cell viability is measured with an MTT assay.

Animal Study:^{^[2]}

Animal Models
Male Kun-Ming strain of mice
Dosages
10, 20 and 40 mg/kg
Administration
by oral gavage

References

Selleck's Nuciferine has been cited by 3 publications

Nuciferine Protects Cochlear Hair Cells from Ferroptosis through Inhibiting NCOA4-Mediated Ferritinophagy [ Antioxidants (Basel), 2024, 13(6)714]	PubMed: 38929153
Nuciferine protects against folic acid-induced acute kidney injury by inhibiting ferroptosis [ Br J Pharmacol, 2021, 178(5):1182-1199]	PubMed: 33450067
Tripartite Motif-Containing 44 is Involved in the Tumorigenesis of Laryngeal Squamous Cell Carcinoma, and its Expression is Downregulated by Nuciferine [ Tohoku J Exp Med, 2021, 254(1):17-23]	PubMed: 34011804

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.